Biotron [ASX: BIT] has expanded its Phase Ib/IIa clinical trial of its BIT225 hepatitis C treatment in an effort to maximise recruitment rates.

Testing will now be conducted at a Brisbane site in addition to the planned trial at a site in NSW.

The trial will be a placebo-controlled, randomised and multi-dose study examining the safety, pharmacokinetics and antiviral activity of the treatment.

The trial should be completed by the end of the year.

BIT225 targets the p7 protein of HCV, and has shown promising results in surrogate models of HCV infection.

http://www.biotechnews.com.au